The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $12.18

Today's change+0.43 +3.66%
Updated November 20 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $12.18

Today's change+0.43 +3.66%
Updated November 20 4:00 PM -5GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc up sharply

Merrimack Pharmaceuticals Inc closed up sharply Monday, rallying (U.S.)$0.43 or 3.66% to (U.S.)$12.18. Over the last five days, shares have gained 2.70%, but are down 70.15% for the last year to date. Shares have underperformed the S&P 500 by 98.63% during the last year.

Key company metrics

  • Open(U.S.) $11.77
  • Previous close(U.S.) $11.75
  • High(U.S.) $12.28
  • Low(U.S.) $11.73
  • Bid / Ask-- / --
  • YTD % change-70.15%
  • Volume233,050
  • Average volume (10-day)151,901
  • Average volume (1-month)184,995
  • Average volume (3-month)183,616
  • 52-week range(U.S.) $11.14 to (U.S.) $64.50
  • Beta1.72
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward0.34×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$7.29
Updated November 20 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-159.70%

Although this company's net profit margin is negative, it is above the industry average and implies that Merrimack Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.04%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue------61
Total other revenue--------
Total revenue00061
Gross profit------58
Total cost of revenue------3
Total operating expense6352788
Selling / general / administrative315624
Research & development14202255
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)-11----5
Other operating expenses, total--------
Operating income-6-35-27-26
Interest income (expense), net non-operating-2-27-2-7
Gain (loss) on sale of assets02----
Other--------
Income before tax-7-60-29-34
Income after tax-5-30-29-34
Income tax, total-2-30----
Net income3512-30-32
Total adjustments to net income--------
Net income before extra. items-5-29-29-32
Minority interest0101
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-5-29-29-32
Inc. avail. to common incl. extra. items3512-30-32
Diluted net income3512-30-32
Dilution adjustment----00
Diluted weighted average shares13131313
Diluted EPS excluding extraordinary itemsvalue per share-0.40-2.18-2.20-2.50
Dividends per sharevalue per share--0.000.00--
Diluted normalized EPSvalue per share-0.93-2.27-2.20-2.11